Hepatitis

The US is close to eliminating hepatitis B in children, but chronic adult infection and a shifting vaccine policy threaten that progress.

Tarik Asselah, MD, PhD, explains why HDV RNA suppression deepened through 2 years with tobevibart plus elebsiran.

Re-engagement strategies for hepatitis B show promise in the US, but data gaps and structural barriers are slowing progress toward WHO elimination targets.

Phase 3 trials show bepirovirsen delivers ~20% functional cure in chronic hepatitis B in just 24 weeks.

Bepirovirsen data show the potential for a functional cure for chronic hepatitis B by lowering HBsAg and boosting immune control.

Chimeric antigen receptor-based immunotherapies show promise when directed at viral targets, but data are limited.

Late diagnosis of hepatitis B and C remains common and is driven by factors like older age, male sex, comorbidities, and limited healthcare engagement.

New evidence affirms hepatitis B birth-dose safety as the CDC makes it optional.

The CDC announced a significant change to the childhood immunization schedule that would reduce vaccine recommendations.

ACIP delayed the vote on the hepatitis B vaccine schedule amid ongoing controversy and misinformation surrounding vaccine safety and infant immunization.

Most US patients eligible for hepatitis B virus (HBV) treatment remain untreated, raising risks of liver disease and complications.

World Hepatitis Day 2025 and its theme, “Hepatitis: Let’s Break It Down,” emphasize the urgent need to remove barriers to prevention, testing, and treatment to reduce liver cancer and eliminate hepatitis by 2030.